NCT03882047

Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)

Efficacy and Safety of Mometasone Furoate Aqueous Nasal Spray vs Placebo and Flonase® (Fluticasone Propionate) in Seasonal Allergic Rhinitis Patients (I94-001)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 313 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of mometasone furoate (SCH 32088) aqueous nasal spray 200 mcg once daily compared to placebo once daily in the treatment of participants with seasonal allergic rhinitis. Flonase (fluticasone propionate) nasal spray 200 mcg once daily has been chosen as the active control for this study.

Conditions

• Rhinitis, Allergic, Seasonal

Interventions

Type	Name	Description
DRUG	Mometasone furoate	Mometasone furoate nasal spray, 200 mg once daily
DRUG	Fluticasone propionate	Fluticasone propionate nasal spray, 200 mg once daily
DRUG	Mometasone furoate placebo	Mometasone furoate placebo matching nasal spray, once daily
DRUG	Fluticasone propionate placebo	Fluticasone propionate placebo matching nasal spray, once daily

Timeline

• Start date: 1994-08-11
• Primary completion: 1994-09-16
• Completion: 1994-09-16
• First posted: 2019-03-20
• Last updated: 2022-02-09
• Results posted: 2019-09-06